Testing TEV-53408 injections for vitiligo, a skin color loss condition
Tests TEV-53408, given as an injection, in adults with vitiligo.
Key facts
- Who runs it
- Teva Branded Pharmaceutical Products R&D LLC
- Where
- Canton, Chicago, Dallas, Fremont, Hot Springs, Irvine, Louisville, Miramar, Pasadena, Portland, Scottsdale, South Jordan, and Webster, United StatesSee the 13 sites
- Trial code
- Registry title
- A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 66 people, planned
- Started
- 11 Nov 2024
- Expected to end
- 31 Jan 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- TEV-53408
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with vitiligo, a condition where patches of skin lose color and turn white. It tests the safety of TEV-53408 given as an injection under the skin.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Active or stable vitiligo, diagnosed at least 3 months ago. Body mass index (BMI) must be 18.5 to 40.0 kg/m2.
- Earlier treatment
- People must stop all vitiligo treatments and procedures during the trial. People who used skin bleaching treatments cannot join. People who had skin cell transplant (melanocyte-keratinocyte transplantation) or other surgery for vitiligo cannot join, unless the last transplant was 2 or more years ago.
Main reasons for not taking part
- Vitiligo caused by chemicals or by immunotherapy
- Other autoimmune diseases that need or may need whole-body immune treatment
- Cancer now or in the last 5 years, except fully treated basal cell skin cancer
- Infectious disease, or alcohol or other substance abuse now or in the past
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- The participant has a diagnosis of active or stable vitiligo for at least 3 months
- The participant has a body mass index (BMI) within the range of 18.5 to 40.0 kg/m2
- A female participant is eligible if she is not pregnant or breastfeeding AND is a woman of nonchildbearing potential OR is a women of childbearing potential using a contraceptive method that is highly effective AND agrees not to donate eggs for the purpose of reproduction for the required period
- A male participant is eligible if he agrees to refrain from donating sperm PLUS remain abstinent from heterosexual intercourse OR use a male condom with a female partner for the required period
- The participant is capable of giving signed, informed consent
- The participant agrees to discontinue all agents and procedures used to treat vitiligo during the treatment period in the trial
- If receiving permitted concomitant medications for any reason other than vitiligo, the participant must be on a stable regimen,
- The participant must agree to avoid prolonged exposure to the sun, must use sunscreen, and must not use tanning booths, sun lamps, or other ultraviolet light sources; NOTE - Additional criteria apply, please contact the investigator for more information
Who cannot take part
- The participant suffers from vitiligo induced by exposure to chemicals or immunotherapy known to induce vitiligo
- The participant has other autoimmune diseases for which systemic immunotherapy is or may be warranted
- The participant has current or history of malignancy or treatment of malignancy in the last 5 years, excluding fully-treated basal cell carcinoma
- Infectious disease
- The participant has a history of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. After 2 or more years since last melanocyte-keratinocyte transplantation procedure, the participants may be included in the trial
- The participant has current or history of alcohol or other substance abuse; NOTE- Additional criteria apply, please contact the investigator for more information
- The participant has donated or received any blood or blood products (white blood cells, platelets, etc) within the 60 days prior to screening or has donated blood or blood products on 2 or more occasions within the 6 months prior to IMP administration, or has donated plasma within 7 days before the screening visit, or has planned donations during the trial
- The participant has used skin bleaching treatments for past treatment of vitiligo or other pigmented areas
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Hamzavi DermatologyCanton, United StatesTaking people
- MetroMed Clinical TrialsChicago, United StatesNo longer taking part
- Dermatology Treatment & Research CenterDallas, United StatesTaking people
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesTaking people
- Burke Pharmaceutical ResearchHot Springs, United StatesTaking people
- University of CA IrvineIrvine, United StatesNo longer taking part
- DS Research of KentuckyLouisville, United StatesTaking people
- Watson Therapeutics Inc. (WTI), USAMiramar, United StatesTaking people
- Pasadena Clinical TrialsPasadena, United StatesNo longer taking part
- Oregon Dermatology and Research CenterPortland, United StatesTaking people
- Scottsdale Clinical ResearchScottsdale, United StatesNo longer taking part
- Jordan Valley DermatologySouth Jordan, United StatesNo longer taking part
- Center for Clinical Studies, LTD. LLPWebster, United StatesNo longer taking part
About the trial
What the trial wants to find out
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
The 3 groups in the trial
- Cohort 1Treatment being tested
Dose A
Treatment: TEV-53408
- Cohort 2Treatment being tested
Dose A
Treatment: TEV-53408
- Cohort 3Treatment being tested
Dose B
Treatment: TEV-53408
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
- Plain-language title
- Testing TEV-53408 injections for vitiligo, a skin color loss conditionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06625177, who can take part
- Record updated
- 29 October 2026